Analytik Jena CEO Klaus Berka Becomes an Advisor of the Fraunhofer IZI
News May 17, 2014
The CEO of Analytik Jena AG, Klaus Berka, has been appointed to the Advisory Board of the Fraunhofer Institute for Cell Therapy and Immunology (IZI).
Fraunhofer IZI, which was founded in Leipzig in 2005, researches and develops solutions to specific problems at the interfaces between medicine, life sciences, and engineering, such as drugs, cell therapy, diagnostics, and biobanks.
"I am pleased that I will have the opportunity as a member of this select board to help see to it that the institute can successfully and effectively continue its work in important pharmaceutical and therapeutic areas. I hope that I will be able to substantively enrich the work of the Advisory Board with my experience," Klaus Berka said. "Communication between science and business has been a very important personal concern of mine for many years."
In its Life Science business unit, Analytik Jena develops instruments, kits, and reagents in the area of biotechnology and molecular diagnostics that address a rapidly growing global market.
A New, Streamlined Approach to Diagnosing and Treating Bowel CancerNews
Researchers at the South Australian Health and Medical Research Institute (SAHMRI) and the University of Adelaide have discovered a faster, more cost-effective way to determine which DNA mutations cause human bowel cancer.READ MORE